TIRATRICOL ( DrugBank: Tiratricol )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 78 | 下垂体前葉機能低下症 | 2 |
| 139 | 先天性大脳白質形成不全症 | 6 |
78. 下垂体前葉機能低下症
臨床試験数 : 494 / 薬物数 : 385 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-003370-35-IT (EUCTR) | 30/04/2020 | 24/05/2021 | Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II | Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II - Triac Trial II | Monocarboxylate Transporter 8 (MCT8) deficiency MedDRA version: 20.0;Level: PT;Classification code 10078564;Term: Thyroid stimulating hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: emcitate Product Code: [emcitate] INN or Proposed INN: Tiratricol Other descriptive name: Tiratricol Product Name: Emcitate Product Code: [Emcitate] INN or Proposed INN: Tiratricol Other descriptive name: Tiratricol | Rare Thyroid Therapeutics International | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 18 | Phase 2 | France;United States;Czechia;Czech Republic;Netherlands;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2019-003370-35-GB (EUCTR) | 28/02/2020 | 07/01/2020 | Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II | Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II - Triac Trial II | Monocarboxylate Transporter 8 (MCT8) deficiency MedDRA version: 20.0;Level: PT;Classification code 10078564;Term: Thyroid stimulating hormone deficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Emcitate INN or Proposed INN: TIRATRICOL Product Name: Emcitate INN or Proposed INN: TIRATRICOL | Rare Thyroid Therapeutics International AB | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 22 | Phase 2 | United States;France;Czech Republic;Netherlands;Germany;Italy;United Kingdom |
139. 先天性大脳白質形成不全症
臨床試験数 : 10 / 薬物数 : 7 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02396459 (ClinicalTrials.gov) | December 7, 2020 | 7/3/2015 | Triac Trial II in MCT8 Deficiency Patients | Tiratricol Treatment of Children With Monocarboxylate Transporter 8 Deficiency: Triac Trial II | Allan-Herndon-Dudley Syndrome | Drug: Triac | Rare Thyroid Therapeutics International AB | Erasmus Medical Center | Recruiting | N/A | 30 Months | Male | 18 | Phase 2 | Netherlands |
| 2 | EUCTR2014-000178-20-CZ (EUCTR) | 04/02/2016 | 23/06/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 40 | Phase 2 | Czech Republic;Belgium;Germany;Italy | ||
| 3 | EUCTR2014-000178-20-IT (EUCTR) | 01/02/2016 | 16/10/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 40 | Phase 2 | Germany;Italy | ||
| 4 | EUCTR2014-000178-20-FR (EUCTR) | 14/01/2016 | 14/12/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | Centre Hospitalier de Toulouse | Not Recruiting | Female: no Male: yes | 40 | Phase 2 | France;Czech Republic;Canada;Belgium;Australia;South Africa;Germany;Italy | ||
| 5 | EUCTR2014-000178-20-BE (EUCTR) | 12/08/2015 | 22/06/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois | Erasmus Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 40 | Phase 2 | Canada;Belgium;Australia;Chile;South Africa;Germany;Italy | ||
| 6 | EUCTR2014-000178-20-DE (EUCTR) | 05/10/2015 | Therapy of MCT8 patients with the thyroid hormone analog Triac. | Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. - Triac Trial in MCT8 patients | This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic clinical phenotype of severe psychomotor retardation due to local hypothyroidism in the brain, in combination with high serum T3 and high normal serum TSH levels that lead to local hyperthyroidism in tissues that do not dependent on MCT8, resulting in tachycardia, low body weight and muscle wasting.;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Téatrois (Tiratricol) Product Name: Téatrois INN or Proposed INN: Tiratricol | Erasmus Medical Centre | NULL | Not Recruiting | Female: no Male: yes | 40 | Phase 2 | France;Czech Republic;Canada;Belgium;Australia;Israel;South Africa;Germany;Italy |